Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals logo
$0.76 -0.01 (-1.56%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$0.77 +0.01 (+1.05%)
As of 06/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Key Stats

Today's Range
$0.73
$0.80
50-Day Range
$0.76
$1.36
52-Week Range
$0.73
$200.00
Volume
226,826 shs
Average Volume
696,875 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Moderate Buy

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

CNSP MarketRank™: 

CNS Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about CNS Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CNS Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about CNS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.36% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 75.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CNS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CNS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.36% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 75.13%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

    • Read more about CNS Pharmaceuticals' insider trading history.
    Receive CNSP Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    CNSP Stock News Headlines

    A new rule goes live in July — and the banks are quietly cashing in
    A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
    See More Headlines

    CNSP Stock Analysis - Frequently Asked Questions

    CNS Pharmaceuticals' stock was trading at $6.02 at the beginning of 2025. Since then, CNSP stock has decreased by 87.4% and is now trading at $0.7590.
    View the best growth stocks for 2025 here
    .

    CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its earnings results on Thursday, May, 15th. The company reported ($1.58) EPS for the quarter.

    CNS Pharmaceuticals's stock reverse split before market open on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

    CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

    Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

    Company Calendar

    Last Earnings
    5/15/2025
    Today
    6/24/2025
    Next Earnings (Estimated)
    8/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CNSP
    Fax
    N/A
    Employees
    5
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $25.00
    High Stock Price Target
    $25.00
    Low Stock Price Target
    $25.00
    Potential Upside/Downside
    +3,193.8%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$14.86 million
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $5.37 per share
    Price / Book
    0.14

    Miscellaneous

    Free Float
    5,458,000
    Market Cap
    $4.14 million
    Optionable
    Not Optionable
    Beta
    2.65
    Options Trading Made Easy - Download Now Cover

    Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

    Get This Free Report

    This page (NASDAQ:CNSP) was last updated on 6/24/2025 by MarketBeat.com Staff
    From Our Partners